心源性休克患者的机械循环支持:法国心脏病学会心脏重症监护病房组立场文件
该立场文件指出心源性休克仍是当代心脏病学的重大挑战,尽管对其病理生理理解加深,管理仅略有改善,过去十年患病率稳定,但1个月死亡率仍约40-60%。正性肌力药和血管升压药是一线治疗但伴随显著危害和已知不良效应,相当数量患者尽管增加儿茶酚胺剂量仍出现难治性心源性休克伴血流动力学不稳定。近期强效机械循环支持装置问世带来重大改变,包括左心室至主动脉循环支持装置和静脉-动脉体外膜氧合提供全肺和循环支持。然而支持其适应证、植入时机及患者和装置选择的证据稀缺,该组旨在提出实用算法以帮助重症监护和心脏监护病房医生。
要点
- 心源性休克过去十年患病率稳定,但1个月死亡率仍约40-60%。
- 正性肌力药和血管升压药为心源性休克一线治疗,但与显著危害和已知不良效应相关。
- 相当数量患者尽管增加儿茶酚胺剂量仍发生难治性心源性休克,伴血流动力学不稳定、关键器官低灌注和/或肺淤血。
- 有效机械循环支持装置包括左心室至主动脉循环支持装置和静脉-动脉体外膜氧合提供全肺和循环支持。
- 支持机械循环支持适应证、植入时机及患者和装置选择的证据稀缺,该组提出实用算法帮助ICU和CCU医生。
适用人群与场景
- 心源性休克患者,尤其是尽管增加儿茶酚胺剂量仍出现血流动力学不稳定、关键器官低灌注和/或肺淤血的难治性心源性休克患者。
处置流程与药物剂量
- 正性肌力药和血管升压药作为心源性休克一线治疗。
- 对难治性心源性休克患者可考虑机械循环支持装置,包括左心室至主动脉循环支持装置和静脉-动脉体外膜氧合。
红旗征与不能漏的情况
- 尽管增加儿茶酚胺剂量仍出现血流动力学不稳定、关键器官低灌注和/或肺淤血,提示难治性心源性休克。
研究设计与关键结果
- 该立场文件由法国心脏病学会心脏重症监护病房组制定,旨在为心源性休克患者机械循环支持的使用提出实用算法,证据有限。
证据类型、等级与局限
- 证据类型:立场文件(专家意见)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该文件帮助ICU和CCU医生在证据有限的情况下,为心源性休克患者选择机械循环支持装置、时机和适应证提供实用算法。
指南或共识出处
- 法国心脏病学会心脏重症监护病房组立场文件,获法国心脏病学会动脉粥样硬化与介入心脏病学组认可。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Cardiogenic shock (CS) is a major challenge in contemporary cardiology. Despite a better understanding of the pathophysiology of CS, its management has only improved slightly. The prevalence of CS has remained stable over the past decade, but its outcome has seen few improvements, with the 1-month mortality rate still in the range of 40-60%. Inotropes and vasopressors are the first-line therapies for CS, but they are associated with significant hazards, and have well-known deleterious effects. Furthermore, a significant number of patients develop refractory CS with haemodynamic instability, causing critical organ hypoperfusion and/or pulmonary congestion, despite increasing doses of catecholamines. A major change has resulted from the recent advent and availability of potent mechanical circulatory support (MCS) devices. These devices, which ensure sustained blood flow, provide a great and long-awaited opportunity to improve the prognosis of CS. Several efficient MCS devices are now available, including left ventricle-to-aorta circulatory support devices and full pulmonary and circulatory support with venoarterial extracorporeal membrane oxygenation. However, evidence to support their indications, the timing of implantation and the selection of patients and devices is scarce. Because these devices are gaining momentum and are becoming readily available, the "Unité de Soins Intensifs de Cardiologie" group of the French Society of Cardiology aims to propose practical algorithms for the use of these devices, to help intensive care unit and cardiac care unit physicians in this complex area, where evidence is limited.
参考来源
- Bonello L, Delmas C, Schurtz G, et al. Mechanical circulatory support in patients with cardiogenic shock in intensive care units: A position paper of the "Unité de Soins Intensifs de Cardiologie" group of the French Society of Cardiology, endorsed by the "Groupe Athérome et Cardiologie Interventionnelle" of the French Society of Cardiology. Arch Cardiovasc Dis. 2018. PMID: 29903693. doi:10.1016/j.acvd.2018.03.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。